Track Geron Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Geron Corporation GERN · Stock Open Geron Corporation in new tab

0.9634 USD
EPS
-0.08
P/B
2.75
ROE
-20.12
Beta
0.61
Target Price
3.50 USD
Geron Corporation logo

Geron Corporation

🧾 Earnings Recap – Q3 2025

Geron Corporation reported third quarter 2025 revenues of $47.2 million, reflecting a 3% decline in net product sales for RYTELO, as the company emphasizes its commitment to increasing utilization and education around its therapy for lower-risk MDS.

  • New patient starts for RYTELO increased significantly to 36% from 30% in the previous quarter, despite an overall revenue decline.
  • The company expanded its prescribing accounts by 15%, adding approximately 150 new accounts, bringing the total to 1,150.
  • Geron is initiating a strategic focus on increasing awareness among healthcare providers and enhancing relationships with key opinion leaders as part of a comprehensive plan to drive sales growth.
  • New Chief Commercial Officer, Ahmed ElNawawi, joins to strengthen the execution of Geron’s commercial strategy and address the challenges in the current marketplace.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-0.08
Book Value0.35
Price to Book2.75
Debt/Equity53.48
% Insiders0.589%
Growth
Revenue Growth0.27%
Estimates
Forward P/E10.74
Forward EPS0.09
Target Mean Price3.50

DCF valuation

Model fair value for Geron Corporation (GERN)
Result
Sign in to run the valuation for GERN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Buy · mean target 3.50 USD (low 2.50, high 5.00) · as of 16 Nov 2026
Low 2.50
Mean 3.50
High 5.00
Price 0.9634
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Geron Corporation Logo Geron Corporation Analysis (GERN)

United States Health Care Official Website Stock

Is Geron Corporation a good investment? Geron Corporation (GERN) is currently trading at 0.9634 USD. Market analysts have a consensus price target of 3.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Geron Corporation is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 0.09.

Investor FAQ

Does Geron Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Geron Corporation?

Geron Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -0.08.

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Exchange Ticker
NMS (United States) GERN
FRA (Germany) GON.F
LSE (United Kingdom) 0IV3.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 22, 2014 1.058
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion